30 closest matches · ranked by relevance
Small Cell Lung Cancer · Extensive Stage Lung Cancer · Chemonaive
Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants
Lung Cancer
Primary: The Objective Overall Response — 7; 12; 7; 19 participants
Lung Cancer
Primary: Overall Response Rate — 65; 50 percentage of participants
Recurrent Non-small Cell Lung Cancer
Primary: Objective Response Rate — 0; 0 percentage of responding patients
Recurrent Small Cell Lung Cancer
Primary: Maximum Tolerated Dose (MTD) of Rovalpituzumab Tesirine — 0.4 mg/kg
Recurrent Small-cell Lung Cancer (SCLC) · Lung Cancer, Small Cell
Primary: Percentage of Participants With Progression-free Survival (PFS) at 3 Months — 65 percentageof participants — p=0.017
Small Cell Lung Cancer
Primary: Objective Response Rate — 6 Participants
Small Cell Lung Cancer
Primary: 8-Week Progression-Free Rate — 0.0; 8.3 percentage of participants
Lung Cancer
Primary: Time to Progression — 123 days
Lung Cancer
Primary: Number of Grade 3/4 Toxicities Patients Experienced on Maintenance Bevacizumab Following Chemoradiation for Limited Stage - Small Cell Lung Cancer (LS-SCLC) — 2; 1; 1; 1…
Lung Cancer
Primary: Response by RECIST Criteria (v 1.0) — 3; 5; 11; 15 participants
Extensive Stage Small Cell Lung Cancer · Limited Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: 6 Week Progression Free Survival — 43 percentage of participants
Recurrent Small Cell Lung Carcinoma
Primary: 18 Week Progression-free Survival Rate — 35; 72 percentage of participants
Carcinoma, Small Cell · Lung Cancer · Small Cell Lung Cancer
Primary: Proportion of Evaluable Participants Who Experience a Partial Response (PR) or Complete Response (CR) Reported Along With an 80% Confidence Interval. — 0.1; 0; 0.2; 0…
Extensive Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: Objective Response Rates (Complete and Partial) Evaluated Using RECIST Criteria — 2 participants
Small Cell Lung Cancer (SCLC)
Primary: Overall Response Rate — 0; 9; 16; 7 Participants
Extensive Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: Objective Response (Confirmed and Unconfirmed, Complete and Partial Responses Per RECIST) — 11; 2 percentage of participants
Urothelial Carcinoma · Urothelial Cancer · Lung Neoplasms
Primary: Phase I: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of EP0057 (CLRX101) in Participants With Refractory Cancers. — 12 mg/m^2
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants
Recurrent Small Cell Lung Carcinoma
Primary: Progression Free Survival (PFS) — 2.1; 3.3 months
Lung Cancer
Primary: Patient Response — 2; 1; 2; 27 participants
Small Cell Lung Cancer
Primary: Determine the Proportion of Previously Treated Small Cell Lung Cancer (SCLC) Patients Whose Disease Has Not Progressed Following 6-weeks (2 Cycles) of Treatment With…
Lung Cancer · SCLC
Primary: Phase I: Maximum Tolerated Dose (MTD) — 30 mg/m^2
Extensive Stage Small Cell Lung Cancer
Primary: Percentage of Participants Alive and Progression-free (PF) at 6 Months — 30.2 Percentage of Participants
Lung Cancer
Primary: Overall Survival (12-month Rate Reported) — 60.1; 50.8 percentage of participants — p=0.2103
Small Cell Lung Cancer · Lung Cancer · SCLC
Primary: 8-Week Progression-Free Rate — 0.567 proportion of patients
Small Cell Lung Cancer
Primary: Overall Survival (OS) — 6.9; 7.0; 7.4 months
Limited Stage Small Cell Lung Cancer · Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 14.5; 10.7 months
Lung Cancer
Primary: Overall Survival at 2 Years — 36.60 percentage of participants